Table 1.
The agonistic (ng and pmol of dihydrotestosterone (DHT) equivalents/g dw) and antagonistic (μg and nmol flutamide (FLU) equivalents/g dw) androgenicity measured in GPC fraction 1 and 2, reversed-phase (RP) fractions, the residual (non-dissoluble fraction at reversed-phase fraction), normal phase (NP) fractions and pooled NP fractions
| DHT equivalents | FLU equivalents | |||
|---|---|---|---|---|
| ng/g sed | pmol/g sed | μg/g sed | nmol/g sed | |
| GPC fraction 1 (16.5-24 min) | << | << | 55 | 200 |
| GPC fraction 2 (29-36 min) | << | << | << | << |
| RP1 | << | << | << | << |
| RP2 | 250 | 890 | + | + |
| RP3 | 120 | 440 | 30 | 110 |
| RP4 | << | << | 6.9 | 25 |
| RP5 | << | << | << | << |
| Residual fraction | << | << | << | << |
| Sum RP | 370 | 1330 | 37 | 130 |
| RP2NP1 | << | << | << | << |
| RP2NP2 | << | << | << | << |
| RP2NP3 | << | << | << | << |
| RP2NP4 | << | << | << | << |
| RP2NP5 | << | << | << | << |
| RP2NP6 | << | << | + | + |
| RP2NP7 | 120 | 420 | << | << |
| RP2NP8 | << | << | << | << |
| Pooled RP2NP1–8 | 320 | 1170 | + | + |
| RP3NP1 | << | << | << | << |
| RP3NP2 | << | << | 6.0 | 22 |
| RP3NP3 | << | << | + | + |
| RP3NP4 | << | << | + | + |
| RP3NP5 | << | << | 2.4 | 8.8 |
| RP3NP6 | << | << | 4.5 | 16 |
| RP3NP7 | 940 | 3400 | << | << |
| RP3NP8 | << | << | << | << |
| Pooled RP3NP1-8 | 110 | 380 | 27 | 98 |
| RP4NP1 | << | << | << | << |
| RP4NP2 | << | << | 3.4 | 12 |
| RP4NP3 | << | << | << | << |
| RP4NP4 | << | << | << | << |
| RP4NP5 | << | << | << | << |
| RP4NP6 | << | << | << | << |
| RP4NP7 | << | << | + | + |
| RP4NP8 | << | << | << | << |
| Pooled RP4NP1–8 | + | + | 9.3 | 34 |
| Sum individual NP | 1060 | 3820 | 16 | 59 |
| Sum pooled NP | 430 | 1550 | 36 | 130 |
<< below limit of detection (>1% induction in the agonistic AR CALUX, >20% inhibition in the antagonistic AR CALUX), + not quantified, i.e. effect only observed in the non-diluted fraction (×1) and not in the diluted fractions (×3–×1,000)